GLP1R and type 2 diabetes mellitus: A meta-analysis of randomized clinical trials evaluating the use of GLP-1 receptor agonists and the occurrence of bone fractures in patients with T2DM observed that these medications did not reduce the incidence of fractures compared with other antidiabetic medications [62].